ALEXANDRIA, VA. – February 7, 2022 – Schizophrenia & Psychosis Action Alliance (S&PAA) has launched a bold agenda to lead a system-wide movement for the improvement of access to medical care, supports and equity for the millions of people living with schizophrenia and psychosis spectrum disorders. To expedite progress, it has appointed world class policy experts, industry executives, and advocates to the organization’s Board of Directors, effective immediately.
“We need to stop punishing and denying medical care to people with serious no-fault brain illnesses. Current barriers to medical care, supportive services and housing are leaving too many people untreated which too often leads to unnecessary illness, homelessness, incarcerations, deaths and unimaginable pain for millions of individuals and their families,” said Gordon Lavigne, CEO.
S&PAA has adopted a new strategic plan for life-saving care, treatment policy and research, consisting of three pillars:
Pillar #1: Promote Policy & Systems Level Change: Build and lead a coalition for systems change.
Pillar #2: Accelerate Disease Understanding and Treatment Access: Improve patient and caregiver outcomes.
Pillar #3: Amplify Treatment & Research Breakthroughs: Build and leverage thought leadership and patient and caregiver networks.
In the months ahead, we will pursue the following activities to improve access and quality of care with the best chances to help end harmful public policy decisions and insufficient treatment options for patients:
- Conduct a global systems-level analysis to identify specific tactics for transforming existing barriers to treatment and care.
- Serve as a catalyst in support of research which can lead to new treatments for patients with a clinical high risk of psychosis spectrum disorders.
- Conduct and publicly share additional data-driven economic research to identify the total societal costs of schizophrenia to establish foundational knowledge that shapes more effective public policies.
- Provide support and education to those living with schizophrenia and psychosis spectrum disorders.
- Partner with industry to ensure new therapeutics are safe, effective, and have the best chances for regulatory success.
To advance our progress, the following distinguished individuals have joined our Board of Directors: